ImmuLogic Pharmaceutical Corporation, the development stage biotechnology company, is considering IPO of common stock. Studies and the problem of high-tech start-ups in these cases. Problems associated with the "windows" for the public offering of shares will be allocated. "Hide
by Josh Lerner Source: Harvard Business School 25 pages.
immulogic pharmaceutical corporation case solution
Publication Date: December 9, 1992. Prod. #: 293087-PDF-ENG
Related Case Solutions & Analyses:
Active Coatings Inc.: Challenges in Managing Product Development (A)
Wainwright Industries (A): Beyond the Baldrige
Value Pricing at Procter & Gamble (B)
Note on European Buyouts
Frito-Lay Inc.: Strategic Transition (A) (Updated)
India (B)
Rhone-Poulenc Rorer Inc.
Sees Candies: Japanese Market Entry (A)
Frost Inc. (A)
Rohm and Haas (B): 1989 Update on Kathon MWX
